CSPG4 and glioma: Another potential target is chondroitin sulfate proteoglycan 4 (CSPG4), also known as melanoma chondroitin sulfate proteoglycan (MSCP), which is expressed in 90% of melanomas as well as in sarcomas and gliomas but rarely expressed in healthy tissues [122,123].